Intrathecal Gemcitabine to Treat Neoplastic Meningitis, IT Gemcitabine
Intrathecal Gemcitabine Therapy for Neoplastic Meningitis: A Phase I and Pharmacokinetic Study
Sponsor: Baylor College of Medicine
Terminated
This trial was terminated. No reason was provided.
Other terminated trials from Baylor College of Medicine
This PHASE1 trial investigates Meningitis and Neoplasms and is currently terminated or withdrawn. Baylor College of Medicine leads this study, which shows 7 recorded versions since 2001 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE1
-
Jan 2021 — Jul 2024 [monthly]
Terminated PHASE1
-
Feb 2020 — Jan 2021 [monthly]
Terminated PHASE1
-
Jun 2018 — Feb 2020 [monthly]
Terminated PHASE1
▶ Show 2 earlier versions
-
Feb 2017 — Jun 2018 [monthly]
Terminated PHASE1
-
Jan 2017 — Feb 2017 [monthly]
Terminated PHASE1
First recorded
Dec 2001
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Baylor College of Medicine
- Brown University
- Children's Hospital of Pittsburg
- Mayo Clinic
- National Cancer Institute (NCI)
- Seattle Children's Hospital
- University of Pittsburgh
For direct contact, visit the study record on ClinicalTrials.gov .